This finding is particularly important because numerous clinical studies have demonstrated that NSCLC patients with exon 19 deletions showed significantly longer median progression-free survival when treated with EGFR-TKIs compared to patients with L858R mutations and uncommon or dual mutations [32–35]. Here, EGFR is linked to non-small cell lung carcinoma.